Ekeke G I, Nduka N
Trop Geogr Med. 1987 Apr;39(2):152-6.
Based on the antisickling properties of structurally similar compounds, uric acid (urate) was investigated and found to possess antisickling activity on sickle cell erythrocytes, in particular at higher urate concentrations. Serum urate levels were subsequently determined for 60 sickle cell patients of both sexes within the age limit of 1-27 years. The mean serum urate values were computed at discrete age groups, and the values obtained were compared with the mean serum urate concentration for 15 normal subjects of both sexes and similar age range. Although a definite age-dependent trend did exist in the mean serum urate concentration in sickle cell disease (SCD), this elevation could not be truly referred to as "hyperuricaemia'. Hence, any possible contribution by elevated serum urate to a gouty trait and SCD bone crisis remains unclear. However, these observed serum urate values corresponded well with those concentrations which inhibited the sickling of sickle cell erythrocytes in vitro, permitting the speculation that the elevated serum urate might well be beneficial to sickle cell patients in a compensatory way.
基于结构相似化合物的抗镰变特性，对尿酸（尿酸盐）进行了研究，发现其对镰状红细胞具有抗镰变活性，尤其是在较高尿酸盐浓度下。随后测定了年龄在1至27岁之间的60例男女镰状细胞病患者的血清尿酸水平。计算了不同年龄组的平均血清尿酸值，并将所得值与15例年龄范围相似的正常男女受试者的平均血清尿酸浓度进行比较。虽然镰状细胞病（SCD）患者的平均血清尿酸浓度确实存在明确的年龄依赖性趋势，但这种升高不能真正称为“高尿酸血症”。因此，血清尿酸升高对痛风性状和SCD骨危象的任何可能贡献仍不清楚。然而，这些观察到的血清尿酸值与体外抑制镰状红细胞镰变的浓度非常吻合，这使得人们推测血清尿酸升高可能以一种代偿方式对镰状细胞病患者有益。
